Holen Sie sich die Stockscreener-App
350.60
2.05%
7.04
Handel nachbörslich:
329.50
-21.10
-6.02%
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
H.C. Wainwright reiterates Praxis Precision stock rating on patent news - Investing.com
PRAX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $1245 - GuruFocus
PRAX Reiterated by BTIG -- Price Target Maintained at $843.00 - GuruFocus
Praxis (NASDAQ: PRAX) counsel adds 78 ESPP shares, holds 26,010.667 - Stock Titan
Praxis (NASDAQ: PRAX) accounting officer adds shares through employee stock purchase plan - Stock Titan
Praxis (PRAX) CEO acquires 126 ESPP shares as compensation - Stock Titan
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN
HighVista Strategies Sells 69,092 Shares of Structure Therapeutics in Q1 2026News and Statistics - IndexBox
Is FDA NDA Progress Amid Wider Losses Altering The Investment Case For Praxis Precision Medicines (PRAX)? - Yahoo Finance
Needham Reiterates Praxis Precision Medicines (PRAX) Buy Recommendation - MSN
(PRAX) Volatility Zones as Tactical Triggers - Stock Traders Daily
[SCHEDULE 13G] Praxis Precision Medicines, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Point72 entities and Cohen report 0.2% stake in Praxis (PRAX) - Stock Titan
Orbis and Allan Gray report 8.9% stake in Praxis Precision Medicines (PRAX) - Stock Titan
Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - MSN
Praxis Precision Medicines stock (US74006W1036): Biotech innovator in CNS disorders - AD HOC NEWS
Praxis Precision Medicines stock hits 52-week high at $358.01 By Investing.com - Investing.com South Africa
Praxis Highlights FDA NDA Acceptances and Strengthened Cash Runway - TipRanks
Praxis (PRAX) widens Q1 2026 loss while advancing four late-stage CNS drugs - Stock Titan
Praxis Precision Medicines stock hits 52-week high at $358.01 - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Given New $715.00 Price Target at Truist Financial - MarketBeat
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $715 - Moomoo
HC Wainwright Issues Pessimistic Outlook for PRAX Earnings - MarketBeat
Lifesci Capital Brokers Lower Earnings Estimates for PRAX - MarketBeat
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Praxis Precision Medicines Maps High-Stakes Launch Path - TipRanks
Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX) - Yahoo Finance
UBS Group AG Sells 7,612 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen - Insider Monkey
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $795 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $166 to $1,245 - Moomoo
Number of shareholders of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis Precision Medicines Q1 Earnings Call Highlights - TradingView
Praxis Precision Medicines, Inc.Common Stock (Nasdaq:PRAX) Stock Quote - FinancialContent
PRAX Maintained by Wedbush -- Price Target Raised to $166.00 - GuruFocus
Deutsche Bank Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $420 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,245 - Moomoo
Praxis Precision Medicines, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $420 From $444, Maintains Buy Rating - marketscreener.com
PRAX Reiterated by BTIG -- Price Target Maintained at $843 - GuruFocus
Praxis Precision Medicines, Inc (PRAX): Investor Outlook on a Biotechnology Challenger with 90% Upside Potential - DirectorsTalk Interviews
TD Cowen Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $554 - Moomoo
Praxis Precision Medicines Q1 2026: Loss Narrows 12.1% to -$3.20/Share - AlphaStreet
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $537 - Moomoo
Jefferies raises Praxis Precision Medicines stock price target on pipeline catalysts - Investing.com UK
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation - MSN
Jefferies raises Praxis Precision Medicines stock price target on pipeline catalysts By Investing.com - Investing.com South Africa
Earnings call transcript: Praxis Precision beats Q1 2026 EPS forecasts By Investing.com - Investing.com Australia
Earnings call transcript: Praxis Precision beats Q1 2026 EPS forecasts - Investing.com
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results - Investing News Network
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):